Filing Flows › Theravance Biopharma (TBPH) › Q1 2026 › vs Q4 2025
Theravance Biopharma (TBPH) Q1 2026 vs Q4 2025 (quarter over quarter)
Theravance Biopharma's revenue fell $28.2M (-61%) from $45.9M in Q4 2025 to $17.7M in Q1 2026.
Theravance Biopharma, Q1 2026: revenue $17.7M (+15% year over year), operating margin -53.6%, net loss $4.9M, operating cash flow $73.3M. The chart draws each line against Q4 2025, the increases inside each band.
Every line
| Line | Q1 2026 | Q4 2025 | Change | % |
|---|---|---|---|---|
| Revenue | $17.7M | $45.9M | −$28.2M | -61% |
| Other income, net | $3.0M | $53.1M | −$50.0M | -94% |
| Income tax benefit | $1.5M | −$12.0M | $13.6M | — |
| Net loss | $4.9M | −$61.0M | $66.0M | — |
| Costs & expenses | $27.2M | $98.9M | −$71.8M | -73% |
| Operating costs | $27.2M | $25.9M | $1.3M | +5% |
| Research & development | $5.8M | $7.4M | −$1.5M | -21% |
| SG&A | $17.7M | $18.5M | −$800K | -4% |
| Operating cash sources | $78.2M | −$67.1M | $145M | — |
| Share-based compensation | $4.5M | $4.5M | $24K | +0.5% |
| Working capital & other | $73.7M | −$71.6M | $145M | — |
| Net loss absorbed | $4.9M | −$61.0M | $66.0M | — |
| Operating cash flow | $73.3M | −$6.1M | $79.3M | — |
Questions
How much did Theravance Biopharma's revenue grow quarter over quarter in Q1 2026?
Theravance Biopharma's revenue fell $28.2M (-61%) from $45.9M in Q4 2025 to $17.7M in Q1 2026.